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Current state of knowledge on Takotsubo Syndrome: a Position Statement from the Taskforce 
on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology 
Executive Summary 
 Nomenclature: ‘Takotsubo syndrome’ is recommended as the formal name for this condition, and 
the term cardiomyopathy is avoided. 
 Diagnosis: A new set of seven diagnostic criteria is proposed incorporating anatomical features, 
ECG changes, cardiac biomarkers, and reversibility of the myocardial dysfunction (Box 1 and 
Diagnostic Algorithm). 
 Clinical subtypes: Classification as ‘primary’ or ‘secondary’ Takotsubo syndrome, depending on 
clinical context and presence of a major medical, surgical, obstetric or psychiatric emergency 
triggering the Takotsubo syndrome episode. 
 Triggers: A stressful trigger is typical but not always present. Triggers can be emotional or 
physical, including acute medical, surgical, obstetric or psychiatric emergencies (Table 1). 
 Anatomical variants: three common and several rare anatomical variants are currently recognised 
(Table 2). 
 Epidemiology: Takotsubo syndrome is increasingly recognised and reported, and many features 
suggest a different pathophysiological condition to coronary atherosclerosis. Takotsubo syndrome 
appears to be more common than previously recognised, but the precise incidence is not known. 
 Complications: Cardiac and non-cardiac complications are common during the acute episode 
(Table 3). 
 Risk Stratification: After confirmed or suspected diagnosis of Takotsubo syndrome, risk 
stratification is recommended to guide treatment (Management Algorithm and Box 4). 
 Treatment: A new management algorithm is proposed, based on risk stratification into higher-risk 
and lower-risk pathways (Management Algorithm). 
 Recurrence: Management of recurrent Takotsubo syndrome and the role of prophylactic treatment 
are discussed. Currently no evidence supports prophylactic treatment after the first presentation. 
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Abstract 
Takotsubo syndrome is an acute reversible heart failure syndrome that is increasingly recognised in 
modern cardiology practice. This Position Statement from the ESC Heart Failure Association provides 
a comprehensive review of the various clinical and pathophysiological facets of Takotsubo syndrome, 
including nomenclature, definition and diagnosis, primary and secondary clinical subtypes, 
anatomical variants, triggers, epidemiology, pathophysiology, clinical presentation, complications, 
prognosis, clinical investigations and treatment approaches. Novel structured approaches to diagnosis, 
risk stratification, and management are presented with new algorithms to aid decision-making by 
practising clinicians. These also cover more complex areas (e.g. uncertain diagnosis and delayed 
presentation) and the management of complex cases with ongoing symptoms after recovery, recurrent 
episodes or spontaneous presentation. The unmet needs and future directions for research in this 
syndrome are also discussed. 
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Introduction 
Takotsubo syndrome is an acute and usually reversible heart failure syndrome first described in 1990 
which is increasingly recognised with access to urgent coronary angiography for patients with acute 
‘cardiac’ chest pain.1 Since the initial description, the clinical community has increasingly recognized 
that this syndrome is distinct from acute coronary syndrome (ACS), although the initial presentation 
has similar features to ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial 
infarction (NSTEMI).
2-10
 Early access to diagnostic coronary angiography has helped identify this 
condition, and the number of case reports, series and registries reported has increased over the last 25 
years, offering different insights into this syndrome.
11
 
To date there have been no randomised trials to define the optimal management of patients with 
suspected Takotsubo syndrome, with respect to both diagnosis and treatment. The increasing variety 
of clinical contexts in which this syndrome has been described implies that multiple 
pathophysiological processes may converge to generate a similar clinical phenotype. As a result, 
clinical decisions are challenging, and many patients currently receive a ‘default’ ACS management 
strategy. 
The published literature on Takotsubo syndrome and related stress-induced cardiac syndromes 
consists of case reports, case series, observational cohorts from screening discharge coding across 
healthcare networks, and data collected from national Takotsubo syndrome registries. These registries 
vary in size but are generally considered small by contemporary standards (<600 patients). This 
current published information is level of evidence C for conventional clinical guidelines. This 
document is a position statement and not a guideline; current evidence was reviewed by a group of 
experts with a specialist interest in Takotsubo syndrome who provided their opinion and consensus of 
the current best practice for the diagnosis and management of patients with Takotsubo syndrome. 
Nomenclature 
Various names have been used to describe the acute appearance now classically described as a 
‘Takotsubo cardiomyopathy’ or ‘Takotsubo syndrome’, following the initial label given by Sato and 
colleagues in 1990 and 1991, which reflects the resemblance of the left ventricle at end-systole to the 
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octopus pots of Japanese fisherman in the Hiroshima fish markets.
12
 Many alternatives names have 
been used, including stress or stress-induced cardiomyopathy,
13
 apical ballooning syndrome,
3
 
ampullary-shaped cardiomyopathy,
14, 15
 and ‘broken heart syndrome’ in the context of bereavement.16 
The authors suggest “Takotsubo syndrome” as a unifying term for this clinical entity. ‘Takotsubo’ has 
now become engrained in both medical literature and teaching, and several Takotsubo registries have 
been established.
17-21
 Since the diagnosis is currently based on a series of clinical observations (see 
below), there is consensus that it fulfils the definition of a clinical syndrome. The term 
‘cardiomyopathy’ implies a primary disease of the cardiac muscle and in clinical cardiology is usually 
applied to a primary heart muscle disorder of genetic or unknown origin. Patients with Takotsubo 
syndrome do not appear to have a primary muscle disorder, and no common genetic basis has been 
identified. The full recovery of patients and the low rate of major adverse cardiac events at follow-up 
in reported series strongly suggest that Takotsubo syndrome is different from the primary 
cardiomyopathies. 
Definition 
Takotsubo syndrome and associated variants are a form of acute and usually reversible heart failure 
syndrome. It may be a form of acute catecholaminergic myocardial stunning, as there is no occlusive 
coronary artery disease to explain the pattern of temporary left ventricular dysfunction observed. 
Patients with Takotsubo syndrome have typical features that must be identified to confirm the 
diagnosis. Several previous diagnostic criteria have been proposed, including those by the Mayo 
Clinic (modified in 2008), the Japanese Takotsubo Cardiomyopathy Group, the Gothenburg Group, 
and the Takotsubo Italian Network.
4, 20, 22-24
 
We have reviewed, adapted and amended these criteria to generate the new 2015 Heart Failure 
Association of the European Society of Cardiology (HFA) Takotsubo Syndrome Diagnostic Criteria 
(Box 1). Although this condition predominantly affects postmenopausal women (~90% of all cases 
reported, particularly in larger cohorts), men and younger women can have this condition. Therefore, 
these demographic features are not a mandatory part of the proposed diagnostic criteria. Takotsubo 
syndrome is reversible—a critical feature that helps to differentiate it from many other acute heart 
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failure syndromes. Timelines of recovery vary depending on the severity of the acute episode. As a 
guide, left ventricular ejection fraction (LVEF) usually recovers by 12 weeks, but ECG changes and 
brain natriuretic peptide (BNP) levels may take 6–12 months to recover and, in some cases, can 
remain permanently abnormal e.g. if myocardial scarring occurs. 
Distinguishing Takotsubo syndrome from acute infective myocarditis can be challenging if there 
is evidence of acute myocardial oedema and inflammation in a typical anatomical distribution, as is 
common during the acute episode of Takotsubo syndrome (Box 2).
25-27
 This could be considered a 
form of acute catecholaminergic myocarditis, given the appearance on T2-STIR cardiac magnetic 
resonance (CMR) and rise in cardiac troponin. A careful history and other clinical features can 
normally differentiate these conditions (e.g. the stressful trigger, if present, in Takotsubo syndrome 
versus the viral prodromal illness with fever in acute infective myocarditis).
28
 
Another difference from the modified Mayo diagnostic criteria is the inclusion of 
phaeochromocytoma. In patients with this condition, and particularly those with an epinephrine-
secreting phaeochromocytoma, acute Takotsubo syndrome may result from a catecholamine storm, in 
an analogous manner to a catecholamine storm after a sudden stressful experience.
29-34
 The 
pathophysiology and clinical phenotype are identical, and therefore the consensus of the authors was 
to include patients with phaeochromocytoma but to consider them as cases of secondary Takotsubo 
syndrome (Table 1). 
Clinical subtypes: primary and secondary Takotsubo syndrome 
Takotsubo syndrome comes to the attention of medical personnel in a variety of clinical scenarios and 
contexts. Cases can be classified as either primary or secondary Takotsubo syndrome. 
Primary Takotsubo syndrome 
In primary Takotsubo syndrome, the acute cardiac symptoms are the primary reason for seeking care, 
usually from emergency medical services, acute cardiac services, or the primary care physician. Such 
patients may or may not have clearly identifiable stressful triggers (often emotional). Potential co-
existing medical conditions may be the predisposing risk factors but are not the primary cause of the 
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catecholamine rise. These cases can be considered primary Takotsubo syndrome, and their clinical 
management depends on the specific complications. 
Secondary Takotsubo syndrome 
A substantial proportion of cases occur in patients already hospitalised for another medical, surgical, 
anaesthetic, obstetric or psychiatric condition. In these patients, sudden activation of the sympathetic 
nervous system or a rise in catecholamines precipitates an acute Takotsubo syndrome as a 
complication of the primary condition or its treatment. We propose that such cases be diagnosed as 
secondary Takotsubo syndrome. Their management should focus not only on the Takotsubo syndrome 
and its cardiac complications but also on the condition that triggered the syndrome. Examples of 
medical conditions reported to trigger secondary Takotsubo syndrome are listed in Table 1. 
Anatomical variants 
Primary and secondary Takotsubo syndromes encompass an array of anatomical variants (Table 2 and 
Figure 1).
35-37
 The initial report of Takotsubo syndrome described what is now considered the 
classical pattern: left ventricular RWMA with apical and circumferential mid-ventricular hypokinesia 
and basal hypercontractility. At end-systole, the left ventricle typically resembles the ‘Takotsubo’ 
with a narrow neck and globular lower portion, giving the appearance of virtual apical ballooning. 
This typical variant with apical dysfunction is present in ~50–80% cases, depending on the series. 
Two other variants are common: the inverted Takotsubo or basal variant, with circumferential 
basal hypokinesia and apical hypercontractility, also referred to as the ‘nutmeg’ or ‘artichoke’ heart, 
and the mid left ventricular (MLV) variant, with circumferential mid-ventricular hypokinesia and both 
basal and apical hypercontractility.
38-40
 The end-systolic appearance of the MLV variant has been 
likened to a Greek vase or the ace of spades; however, the basal variant also can also resemble the ace 
of spades (Figure 1). In both of these variants, reversible LV dysfunction affects more than one 
coronary territory, usually in a circumferential pattern, in the absence of culprit coronary artery 
disease. Rarer variants include biventricular apical dysfunction, dysfunction sparing the apical tip 
(possibly a form of MLV Takotsubo), and isolated RV Takotsubo syndrome.
36, 41-43
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The affected LV segments may recover at different rates, a possible explanation for the various 
anatomical variants observed. Intriguingly, Takotsubo syndrome may recur as a different anatomical 
variant in the same patient, suggesting that a person can be susceptible to more than one subtype.
44, 45
 
Epidemiology 
Several series of Asian and Western (predominantly Caucasian) populations suggest that 1–2% of 
patients with suspected ACS are eventually diagnosed with Takotsubo syndrome.
7, 37
 In those series, 
the incidence of Takotsubo syndrome was likely underestimated. The possibility of pre-hospital 
sudden cardiac death from Takotsubo syndrome was not considered, and with increasing awareness 
and more widespread access to early coronary angiography, Takotsubo syndrome is now recognised 
more frequently. 
The largest reported cohorts are from the Nationwide Inpatient Sample (NIS-USA). However 
these reports were based on ICD-10 discharge coding, with no uniform system for ensuring correct 
diagnosis or estimating the number of cases missed. This registry represents ~20% of all US non-
federal community hospitals. The first NIS-USA study reported data on 6837 patients with Takotsubo 
syndrome from 2008.
46
 The second NIS-USA study reported data from 24,701 patients from 2008–
2009; it appears to be a 24-month dataset, but may include patients in the first study.
47
 These numbers 
imply that there are ~50,000–100,000 cases per annum in the USA, with similar estimated numbers in 
Europe. 
In the first study, Takotsubo syndrome was diagnosed in 0.02% of all acute hospitalizations 
(6837/33,506,402 patients).
46
 The majority (90%) were elderly postmenopausal women (66– 80 years 
of age), a demographic repeated across many published cohorts. The risk factors included smoking, 
alcohol abuse, anxiety states, and hyperlipidaemia. The second study, and largest cohort to date, 
reported details of 24,701 patients with a discharge code for Takotsubo syndrome. The demographics 
were similar to those in the first study: 89% were women, the mean age was 66.9 ± 30.7 years, and 
most patients (59.6%) were ≥65 years old.47 
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Gender differences 
Takotsubo syndrome occurs predominantly in postmenopausal women. The German Takotsubo 
syndrome registry includes 324 patients; 91% are female (mean age 68 ± 12 years) and 9% are male 
(mean age 66 ± 12 years). The demographic and clinical characteristics were similar in men and 
women.
17
 However, emotional stress or the absence of identifiable triggers was more common in 
women. Conversely, a physical stressful triggering event, shock, or resuscitation on presentation was 
more common in men, who also had higher levels of cardiac biomarkers (troponin). In the larger of 
the two NIS-USA cohorts, the mortality rate was higher in men (8.4% vs 3.6%, p < 0.0001), perhaps 
reflecting the higher frequency of underlying severe critical illness and secondary Takotsubo 
syndrome (36.6% in men vs 26.8% in women, p < 0.0001).
47
 
Age 
Elderly patients are considered to be at higher risk of Takotsubo syndrome and related major 
complications, and less than 10% of patients are below 50 years of age.
46, 48
 In the Takotsubo Italian 
Network, Takotsubo syndrome patients older than 65 years have a greater prevalence of hypertension, 
cerebrovascular disease, a lower glomerular filtration rate, and a lower LVEF at discharge compared 
to younger patients. Older adults (≥75 years) have higher rates of in-hospital complications and in-
hospital mortality (6.3% vs 2.8% overall in-hospital mortality).
18
 
Pathophysiology 
The pathophysiology of Takotsubo syndrome is complex and reflects the integrated and systemic 
physiological responses to acute, severe stress and the cardiovascular responses to sudden surges in 
endogenous or exogenously administered catecholamines. The pathophysiology has been extensively 
reviewed elsewhere.
10, 49-52
 
Catecholamines appear to have a central role in the pathophysiology of Takotsubo syndrome, as 
the trigger is often a sudden, unexpected stress; signs of sympathetic activation are present at 
presentation, and secondary medical triggers can also lead to extreme sympathetic activation. There 
are two initial elements of the physiology to consider. The first is the cognitive centres of the brain 
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and hypothalamic-pituitary-adrenal (HPA) axis, and how much epinephrine and norepinephrine are 
released in response to a given stress (i.e., the ‘gain’ of the HPA axis). The second is the response of 
the cardiovascular system (including the myocardium, coronary arteries, and peripheral vasculature) 
and the sympathetic nervous system to the sudden sympathetic activation and surge in circulating 
catecholamines. 
Serum catecholamine levels at presentation are significantly higher than resting levels in the same 
patient or in comparable patients with acute heart failure due to acute myocardial infarction (MI), 
suggesting the potential for excessive HPA gain and epinephrine release.
53
 Iatrogenic Takotsubo 
syndrome has been reported after administration of sympathomimetic drugs (e.g. dobutamine in stress 
echocardiography).
54
 
Several hypotheses have been proposed to explain the unique cardiac appearance in Takotsubo 
syndrome and the cardiac response to severe stress. These hypotheses can be broadly divided into 
vascular and myocardial causes (Box 3) and may not be mutually exclusive, as the entire 
cardiovascular system is exposed to the same catecholamine storm. Many of these hypotheses are still 
being investigated, as there is no current proven pathophysiological mechanism to explain Takotsubo 
syndrome. There may be a synergistic combination of more than one factor, and mechanistic studies 
have yielded conflicting results. 
Genetic susceptibility 
The stressful trigger implies that the pathophysiology of Takotsubo syndrome has a strong 
environmental component. However, it is conceivable that some people have a genetic predisposition 
to stress-induced Takotsubo syndrome. Although the syndrome is not considered a primary genetic 
cardiomyopathy, a number of studies have explored the possibility of genetic risk factors. A genetic 
predisposition has been suggested based on the few familial Takotsubo syndrome cases described.
55-58
 
Conflicting results have been published regarding the presence or absence of functional 
polymorphisms in relevant candidate genes, such as α1-, β1- and β2-adrenergic receptors, GRK5, and 
oestrogen receptors. These studies had relatively small numbers of subjects. Resolving these conflicts 
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will require high-quality phenotyping, identification of candidate genes, and sharing of high-
number/high-quality data in a Takotsubo syndrome network. 
Clinical presentation and diagnosis 
The typical patient with primary Takotsubo syndrome is a postmenopausal women who has 
experienced severe, unexpected emotional or physical stress.
4
 This may be unheralded or on the 
background of elevated levels of stress or anxiety, including in some cases a formal diagnosis of 
anxiety or panic disorder.
46, 59
 However, most patients do not have prior history of stress-related 
psychological conditions. Nevertheless, it is important to remember that 10% of cases in the largest 
reported series (NIS-USA) were men or younger women, and 30–35% of cohort series report classical 
cases in patients with no identifiable stressful trigger.
46
 Thus, gender, menopausal status, and stressful 
triggers are not mandatory features and are not included in our HFA diagnostic criteria. 
Patients with Takotsubo syndrome typically present with acute chest pain of cardiac origin 
(angina), breathlessness, and palpitations due to sinus tachycardia or arrhythmia; in more severe 
cases, presyncope or syncope due to ventricular tachyarrhythmias, severe left ventricular outflow tract 
obstruction (LVOTO), or cardiogenic shock may be present. Patients may describe a wave of pressure 
from the chest to the neck and into the head, consistent with the acute catecholamine and hypertensive 
surge and frequently associated with diaphoresis and heightened anxiety. 
Such patients should prompt urgent clinical evaluation and rapid acquisition of a resting 12-lead 
ECG. These findings should activate an ACS treatment pathway according to the ESC guidelines and, 
where appropriate, urgent coronary angiography
60
 (see Diagnostic Algorithm). CT coronary 
angiography may be considered in stable cases, particularly if the patient is pain free and cardiac 
imaging (e.g. echocardiography) shows typical features of Takotsubo syndrome.
61
 
Once the diagnosis of Takotsubo syndrome is suspected in the catheterization laboratory, early 
cardiac imaging and assessment of cardiac biomarkers can help exclude MI and further stratify risk. 
Given the spectrum of clinical and anatomical patterns, the presence or absence of stressful triggers, 
and the potential presence of coronary artery disease or prodromal viral illnesses, borderline cases 
exist (see Diagnostic Algorithm). In such cases, CMR imaging with late gadolinium enhancement 
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(LGE) may be helpful.
35, 36
 CMR is also complementary to echocardiography to detect complications 
and aid risk stratification and has better sensitivity for detecting LV apical thrombus. 
Secondary Takotsubo syndrome in specific clinical settings 
Takotsubo syndrome can complicate a wide variety of acute medical and surgical conditions, 
including elective non-cardiac procedures (see Secondary Takostubo syndrome section and Table 1). 
Iatrogenic causes during catecholamine administration (e.g., dobutamine stress echocardiography) 
have also been reported. Therefore, clinicians should be alert to Takotsubo syndrome in numerous 
clinical settings, including the acute medical unit, endocrinology ward, neurology ward, anaesthetic 
room, intensive care units (including neuro-intensive care unit), obstetric unit, and psychiatric ward. 
Takotsubo syndrome can be fatal because of mechanisms discussed below (see Complications 
and acute prognosis section). Many of these complications can be readily detected post-mortem in a 
confirmed case of Takotsubo syndrome. More difficult is the case of sudden non-hospital cardiac 
death in a patients with a stressful precipitant and a structurally normal heart and coronary arteries.
62
 
These cases may have medico-legal or criminal implications, for example where sudden death occurs 
during restraint in police custody or in the psychiatric department. A more precise set of 
histopathological criteria is needed to help in post-mortem evaluation and diagnosis of Takotsubo 
syndrome as a cause of stress-induced sudden death. 
Diagnostic investigations 
Biomarkers 
Cardiac troponin measured by conventional assays (not high sensitivity) is elevated in more than 90% 
of patients with Takotsubo syndrome. However, the rise in serum troponin or creatinine kinase is 
disproportionately low relative to the extent of RWMA and cardiac dysfunction (i.e., widespread 
segmental akinesia/hypokinesia of >5 segments and frequently >9 segments in the 17-segment 
model).
48
 
During the acute phase of Takotsubo syndrome, serum cardiac natriuretic peptides [BNP or the N-
terminal fragment of brain natriuretic peptide (NT-proBNP)] are almost always elevated, frequently to 
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extremely high levels that correlate more closely with the degree of ventricular wall motion 
abnormality.
63-66
 The limited evidence to date suggests that BNP and NT-proBNP are more useful 
diagnostic biomarkers than troponin, and it is recommended that they be measured in all suspected 
cases if the assay is available. Since normal levels are extremely rare in Takotsubo syndrome, an 
elevated natriuretic peptide level is included in the new diagnostic criteria (Box 1). NT-proBNP is a 
valuable marker of myocardial deterioration and recovery. Low NT-proBNP at admission may 
reliably indicate a favourable prognosis and hence is included in our proposed risk stratification 
criteria (Box 4). 
Other biomarkers have been reported in research studies but are not currently recommended in 
routine practice. Serum catecholamines (epinephrine, norepinephrine, dopamine), neuropeptide-Y, 
and serotonin are typically elevated in Takotsubo syndrome.
53
 Catecholamine levels are two to three 
time higher in patients with Takotsubo syndrome than in those with acute MI (Killip class III) at 
admission. This finding was reinforced by another study, although not all patients presented with 
elevated serum catecholamines.
5, 67
 In a recent study, the profile of circulating microRNAs (small 
noncoding RNA sequences) differed in Takotsubo syndrome and STEMI patients,
68
 supporting a 
different pathophysiology and the potential for developing future diagnostic biomarkers. 
Electrocardiography 
ECG abnormalities are present in more than 95% of Takotsubo syndrome patients during the acute 
phase.
7, 48, 69-71
 Daily ECGs are helpful, as a typical evolution has now been defined, and the potential 
for worsening of QT interval is important in risk stratification and may help distinguish Takotsubo 
syndrome from STEMI.
72
 However ECG criteria alone are not sufficient to differentiate Takotsubo 
syndrome from STEMI.
73
  
The ECG abnormalities during the acute phase (<12 hours) are ST-segment elevation, ST-
segment depression, new left bundle branch block and sometimes Q-waves, with deep and widespread 
T-wave inversion and significant QT prolongation developing 24–48 hours after the onset of 
symptoms or precipitating stressful trigger (when present).
70
 If presentation is delayed, T-wave 
inversion and QTc prolongation without ST segment elevation might be observed. The QTc 
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prolongation is often pronounced (>500 ms), predisposing to torsades de pointes and ventricular 
fibrillation.
17, 70
 Significant QTc prolongation is seldom seen in STEMI caused by coronary occlusion 
and may help to differentiate the two conditions retrospectively; however, it should not be used for 
prospective diagnosis. A minority of Takotsubo syndrome patients may present with a normal ECG 
but this is atypical. 
Coronary angiography and left ventriculography 
Most Takotsubo syndrome patients should have urgent coronary angiography to exclude STEMI or 
NSTEMI because they present with cardiac chest pain and have ST elevation or other changes that 
could be interpreted as an ACS. In Takotsubo syndrome, the epicardial coronary arteries are typically 
normal and unobstructed; however, given the predilection for older patients, bystander coronary artery 
disease can be present. If so, it is important to consider whether the coronary artery disease is 
sufficient to cause the degree or pattern of LV dysfunction. Several studies reviewing cohorts of 
Takotsubo syndrome patients report bystander coronary artery disease in up to 10% of cases.
74, 75
 
Although not causative, bystander coronary artery disease is a risk factor for more severe heart failure 
during the acute episode (Box 4). Intravascular ultrasound studies have demonstrated that plaque 
rupture or intracoronary thrombosis is not present in Takotsubo syndrome.
76
 Once causative coronary 
occlusion, including acute plaque rupture, thrombus formation, and coronary dissection, has been 
excluded, ventriculography should be performed unless there is a contraindication, since 
ventriculography will frequently be diagnostic for Takotsubo syndrome. This is important as the wall 
motion abnormalities may recover in hours and may be missed if imaging is delayed. The typical 
pattern of wall motion abnormality is the apical and mid-wall hypokinesis that earned this condition 
its original ‘Takotsubo’ label. However, other anatomical variants may occur (see Anatomical 
Variants, Figure 1, and Table 2). 
Echocardiography 
Transthoracic echocardiography with colour and tissue Doppler should be the first non-invasive 
imaging technique to verify a suspected diagnosis of Takotsubo syndrome. Transthoracic 
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echocardiography can assess LV morphology and function, identify anatomic variants, detect 
potential complications (e.g. LVOTO, mitral regurgitation, RV involvement, thrombus formation, and 
cardiac rupture) and monitor recovery.
77-79
 Key echocardiographic features during the acute phase 
consist of a large area of dysfunctional myocardium extending beyond the territory of a single 
coronary artery and usually characterised by symmetrical regional abnormalities involving the mid-
ventricular segments of the anterior, inferior, and lateral walls (a circumferential pattern).
77
 Among 
227 patients enrolled in the Takotsubo Italian Network, low LVEF, elevated E/e´ ratio, reversible 
moderate-to-severe mitral regurgitation, and age ≥75 years correlated independently with major 
adverse events (acute heart failure, cardiogenic shock, and in-hospital death).
80
 
Cardiac magnetic resonance 
CMR provides 3D anatomical information that can distinguish Takotsubo syndrome from other 
cardiac diseases and can help to elucidate its cause and pathophysiology.
35
 It can accurately assess 
both LV and right ventricular (RV) regional function and demonstrate the typical patterns of RWMA 
(Figure 1 and Table 2). Takotsubo syndrome involves the RV in up to one third of patients, and CMR 
often provides more complete views of the RV than echocardiography.
35
 CMR is superior to 
echocardiography in detecting apical LV thrombi, and patients with large areas of apical akinesia may 
benefit from CMR if echocardiography is unclear.
81
 
During the acute phase of Takotsubo syndrome, T2-weighted CMR shows oedema of the LV 
myocardium as high signal intensity with a diffuse or transmural distribution in a distribution 
consistent with the wall motion abnormality. These features help distinguish between Takotsubo 
syndrome from myocarditis and acute MI.
25-28, 82
 
Typically, LGE is usually absent in Takotsubo syndrome and its absence is an important 
distinguishing feature from MI.
35
 It is controversial, however, whether minor LGE may be present in 
some patients with Takotsubo syndrome during the acute phase but absent at follow-up CMR. The 
frequency of LGE depends on the threshold of signal intensity used to define its presence.
83, 84
 
Atypical cases with small areas of persistent apical transmural LGE have been reported. 
If available, CMR should be considered in all patients with suspected Takotsubo syndrome in the 
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acute phase (within 7 days). If availability is limited, it should be reserved for borderline and 
indeterminate cases (see Diagnostic Algorithm). It is also useful to confirm recovery of ventricular 
function on follow-up and to exclude MI or other conditions that can mimic acute Takotsubo 
syndrome. 
Coronary computed tomography angiography (CCTA) 
In diagnosing Takotsubo syndrome, it is essential to exclude coronary occlusion and significant 
coronary stenosis. This evaluation is usually done invasively, as the patient typically presents with a 
clinical picture closely resembling that of acute MI. However, for a delayed presentation (>48 hours 
after chest pain starts and the patient is pain free at the time of presentation) or for retrospective 
evaluation of a patient with the typical history of Takotsubo syndrome weeks or months previously, 
coronary stenoses can also be excluded by CCTA (Box 4). Acquiring information throughout the 
cardiac cycle (spiral or helical acquisition mode) during the acute phase can also demonstrate the 
typical pattern of systolic dysfunction but at the price of a higher radiation exposure.
85
 
Currently there is no evidence for delaying invasive coronary angiography in patients with 
ongoing acute chest pain and acute ECG changes. The ESC guidelines for STEMI or ACS should be 
followed until culprit coronary artery disease has been excluded.
60, 86
 
Radionuclide imaging 
The role of radionuclide imaging in the diagnosis and management of Takotsubo syndrome is 
undetermined. When CMR is unavailable, myocardial perfusion scintigraphy may help exclude 
infarction in uncertain cases, and there are reports of normal or mildly reduced perfusion in the 
dysfunctional segments, but out of keeping with the scale of contractile dysfunction.
87-89
 
Iodine-123 meta-iodo-benzyl-guanidine (mIBG) has been used to image myocardial sympathetic 
nerve terminal activity and to detect adrenal or ectopic phaeochromocytoma, which may be clinically 
relevant in these patients, although its precise role remains to be determined. During the acute phase, 
there is reduced mIBG in the dysfunctional myocardial segments, consistent with a regional 
disturbance of sympathetic neuronal activity.
87, 89
 The abnormalities can persist for several months, 
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and mIBG scintigraphy may have a role in cases without a diagnosis or when the presentation is 
remote from an acute episode (Box 4). Ideally, mIBG imaging should be combined with myocardial 
perfusion scintigraphy to exclude infarction; it is unknown whether persisting innervation 
abnormalities or increased mIBG washout, reflecting increased sympathetic tone, provides prognostic 
information. 
Cardiac positron emission tomography using 
18
F-2-fluoro-deoxy-glucose has shown abnormal 
glucose metabolism in the context of normal myocardial perfusion in patients with Takotsubo 
syndrome; however, it currently has been used only in a research context.
88, 90
 
Complications and acute prognosis 
Takotsubo syndrome has generally regarded a relatively benign disease with rapid recovery of LV 
function. However, growing evidence suggests it is a more serious acute cardiac disorder with a 
variety of complications in ~52% of patients (Table 3).
80, 91, 92
 
Acute heart failure 
Systolic heart failure is the most common complication in the acute phase of Takotsubo syndrome, 
occurring in 12–45% of cases.4, 6, 7, 17, 80, 92 Independent predictors of acute heart failure are advanced 
age, low LVEF at presentation, higher admission and peak troponin levels, and a physical stressor 
preceding the onset of symptoms. Mechanical ventilation, inotropic support, and intra-aortic balloon 
pumping have been required in a substantial number of cases (28%, 38%, and 17%, respectively).
93
 In 
some patients, pulmonary oedema due to acute LV dysfunction is exacerbated by mitral regurgitation, 
LVOTO or both. 
Left ventricular outflow tract obstruction (LVOTO) 
During the acute phase, a dynamic intraventricular pressure gradient due to mitral valve systolic 
anterior motion may develop as a consequence of myocardial stunning of the apical segments and 
hypercontraction of the basal LV myocardium. Significant LVOTO with gradients of 20–140 mm Hg 
have been observed in 10–25% of patients, often accompanied by mitral regurgitation.7, 80, 94 A mid-
ventricular or LVOTO gradient >25 mm Hg is considered haemodynamically significant, and a 
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gradient ≥40 mm Hg is a high-risk factor. Abnormal Q waves, hypotension, and cardiogenic shock are 
more frequent in these patients. Use of inotropic drugs or nitrates may exacerbate LVOTO, whereas 
beta-blockade with propranolol decreases the gradient.
95, 96
 Normally LVOTO resolves spontaneously 
over a few days. 
Mitral regurgitation 
Acute mitral regurgitation is another potentially serious complication, occurring in 14-25% of 
patients.
97, 98
 LVEF is lower and pulmonary artery pressure is higher in patients with significant 
regurgitation, who present more often with acute heart failure or cardiogenic shock. Two independent 
mechanisms may cause acute mitral regurgitation: systolic anterior motion of the mitral valve in 
association with dynamic LVOTO and apical tethering of the subvalvular mitral valve apparatus.
98, 99
 
In most cases, the mitral regurgitation decreases as LV function returns to normal, although recovery 
may be slower than in patients without acute mitral regurgitation. 
Cardiogenic shock 
Cardiogenic shock, primarily due to acute LV dysfunction, occurs in 4–20% of patients with 
Takotsubo syndrome and may be exacerbated by RV involvement, LVOTO, or acute mitral 
regurgitation. Echocardiography may identify the mechanism and help guide therapy. The mortality 
of cardiogenic shock in Takotsubo syndrome is high (17–30%).6, 80, 91, 92, 100 
Arrhythmias 
Arrhythmias are common in patients with Takotsubo syndrome. New atrial fibrillation has been 
reported in 5–15% of cases.6, 92, 101, 102 This arrhythmia further reduces cardiac output and is often 
associated with the onset of heart failure. Ventricular arrhythmias occur in 4–9% of patients during 
the acute phase of the syndrome,
6, 92, 101-103
 causing cardiac arrest in 4–6% of cases. In rare instances, 
ventricular arrhythmias have been documented weeks after the first manifestation of Takotsubo 
syndrome, when LV function had already normalized. Bradycardia due to atrioventricular block and 
asystole has also been described.
92
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Thrombus formation 
Thrombus in the akinetic ventricular apex is observed in 2–8% of Takotsubo syndrome patients, 
occasionally resulting in stroke or arterial embolism.
92, 104, 105
 Best visualized by CMR imaging in 
early postcontrast acquisition sequences, most thrombi develop 2–5 days after symptom onset, when 
LV function is still depressed. However, new thrombus formation and subsequent embolism have also 
been described 14 days after symptom onset, when LV systolic function had already returned to 
normal. LV thrombi may resolve with 2 weeks of therapeutic anticoagulation, but a longer course 
(usually 3 months) should be considered, and follow-up imaging is advisable to confirm recovery of 
apical contractile function.
106
 Prophylactic anticoagulation in higher-risk Takotsubo syndrome cases 
has an as-yet undetermined role but may be considered (see Management Algorithm for higher-risk 
individuals). 
Pericardial effusion 
Acute pericarditis with recurrent chest pain, reappearance of ST-segment elevation, and a small 
amount of pericardial effusion has been observed in some patients during the recovery phase of 
Takotsubo syndrome.
107
 CMR imaging early after admission has detected small pericardial effusions 
in ~43% of patients. Pericardial tamponade requiring pericardiocentesis is rare (0.05%).
108
 
Ventricular wall rupture 
Serious mechanical complications, including ventricular free wall rupture or interventricular septal 
perforation are rare (<1%); they occur 2–8 days after symptom onset, often with persistent ST 
elevation.
92, 109, 110
 A high outflow tract gradient may favour rupture of the LV free wall. One case of 
RV rupture has been described. Interventricular septum perforation and acquired ventricular septal 
defect can complicate Takotsubo syndrome and may be successfully treated by surgery.
111, 112
 
Right ventricular involvement 
Patients with biventricular involvement generally have a more severe clinical course. RV involvement 
assessed by echocardiography or magnetic resonance imaging has been reported (18–34% cases) and 
is associated with older age, lower LVEF, a higher frequency of heart failure, pleural effusion and a 
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longer hospital stay.
92, 113
 Rarely, a pressure gradient or an apical thrombus may be present in the right 
ventricle. 
Mortality during the acute episode 
In large studies and registries of Takotsubo syndrome patients, the in-hospital mortality rate is 2–5%; 
death is mainly caused by refractory cardiogenic shock or ventricular fibrillation.
80, 91, 92
 In a meta-
analysis of 2120 patients in 37 studies, the in-hospital mortality rate was 4.5%,
114
 consistent with the 
4.2% in-hospital mortality reported in the large NIS-USA Takotsubo syndrome cohorts.
46, 47
 
Recurrence 
Data on recurrence of Takotsubo syndrome are limited by the relatively short observation period in 
most studies. Five-year recurrence rates of 5–22% have been reported, with the second episode 
occurring 3 months to 10 years after the first.
4, 6, 22, 100
 Recurrence of a different anatomical variant has 
been reported. Prognosis should be individualised according to the likelihood of recurrence, the 
triggering event, and co-existing medical conditions. If a patient has a recurrence, long-term clinical 
follow up should be considered (see Management Algorithm). 
Long-term prognosis  
There are conflicting reports and data regarding the long-term survival of patients after their initial 
episode of Takotsubo syndrome. In two studies, 4-year survival was not different from that of an age- 
and gender-matched population.
115, 116
 However, in two other studies, survival at 3 years was 
significantly lower than that of a matched general population.
100, 117
 In the prospective 
SWEDEHEART registry, 3-year mortality was similar to that of NSTEMI and STEMI controls, and 
these results have been recently been confirmed by data from the INTER-TAK registry.
91, 118
 Excess 
mortality occurs predominantly in the first 4 years after diagnosis and is related to non-cardiac 
illnesses such as malignancy.
116, 119
 Data on the long-term prognosis of patients with Takotsubo 
syndrome are limited. 
Most patients recover rapidly after the acute episode and have no symptoms. However, there is 
increasing evidence that physiological abnormalities persist after resting contractile abnormalities 
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have returned to normal ‘macroscopically’, and some patients have persistent cardiac symptoms after 
the acute episode,
116
 including angina, exertional breathlessness, palpitation, and a tremulous anxiety 
state, perhaps reflecting heightened sympathetic tone. Although the coronary arteries are unobstructed 
and ventricular function has recovered macroscopically, it is helpful to document objective evidence 
of ongoing cardiac abnormalities to reassure the patient and to guide treatment. Twenty-four-hour 
Holter ECG monitors to identify atrial arrhythmias or inappropriate sinus tachycardia (continuous or 
paroxysmal) may be helpful, and 24-hour ambulatory blood pressure monitoring may detect transient 
and inappropriate hypertensive episodes. Persistent ECG changes and sometimes other evidence of 
autonomic disturbance can provide objective evidence and exclude non-cardiac explanations for 
ongoing symptoms. The absolute frequency of incomplete recovery is not well reported, and 
management of these patients requires specialist care. 
Clinical management (see Diagnostic and Management Algorithms) 
General considerations 
There are no randomised clinical trials to support specific treatment recommendations in Takotsubo 
syndrome. A key feature of Takotsubo syndrome is recovery of normal cardiac function. The major 
objective of in-hospital treatment should be supportive care to sustain life and to minimise 
complications during recovery. In mild cases, no treatment or a short course of limited medical 
therapy may be sufficient. In severe cases complicated by progressive circulatory failure and 
cardiogenic shock, early mechanical support early should be considered as a ‘bridge-to-recovery’. 
Diagnostic and management algorithms have been generated to help guide clinical decision-
making. Risk stratification is essential to select treatment for patients at greatest risk of complications 
and to minimise interventions in patients at low risk where evidence for treatment is lacking. Given 
the lack of evidence from randomised controlled trials, the diagnostic and management algorithms are 
based on expert consensus and require validation in prospective trials. One overriding consideration in 
a condition with a high rate of functional recovery is to respect the fundamental ethical principle in 
medicine: primum non nocere (first, do no harm). 
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Once the diagnosis is confirmed, it may be helpful to enquire about previous episodes of 
unexplained chest pain, and in particular hospital admissions for chest pain or MI. In some cases, the 
index presentation is clearly a recurrence of Takotsubo syndrome (see Prevention of recurrence 
section). 
In diagnosing borderline cases, it may be helpful to review the history to identify stressful triggers 
or co-existing medical conditions that may lead to sudden rises in sympathetic neural activity and 
systemic catecholamine levels. If the diagnosis is still uncertain, cardiac mIBG may be considered to 
evaluate regional myocardial sympathetic innervation and tone. It may be necessary to reserve 
judgement until follow-up imaging at 3 months confirms recovery of any RWMA present during the 
acute phase and clarifies the presence or absence of permanent LGE by CMR. 
Risk stratification 
Takotsubo syndrome has been generally regarded a relatively benign disease with rapid recovery of 
LV function. However, a variety of complications occurs in ~52% of the patients (Table 3).
80, 91, 92
 
After diagnosis, we recommend that patients with Takotsubo syndrome be triaged according to the 
risk stratification system shown in Box 4 and the Management Algorithm. Higher risk is defined as the 
presence of at least one major or two minor risk factors, with clinical judgement based on their 
severity. 
Given the high risk of complications, where possible all patients with Takotsubo syndrome should 
be admitted to a coronary care unit or high-dependency unit with ECG monitoring for the first 24 
hours while the investigations and risk stratification are completed. Patients considered at higher risk 
of in-hospital mortality should be monitored in a high-dependency or coronary care unit. Patients at 
lower risk may be transferred to wards with lower levels of monitoring and potentially discharged 
early. Risk is a continuous variable and may change as new risk factors are identified. This risk 
stratification system is a clinical tool to guide clinicians caring for patients with Takotsubo syndrome. 
However, given the absence of randomised trial evidence, it does not replace clinical judgement. 
Validation of risk stratification algorithm requires a prospective study, and therefore this proposal is 
currently based on expect opinion (level of evidence C). 
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Management of lower-risk cases of Takotsubo syndrome 
In milder cases with an LVEF >45% and no complications, the patient may be considered for early 
discharge from hospital. Before discharge, however, a review of medication is recommended, as many 
patients will have been started on treatment for ACS before coronary angiography, and indications for 
antiplatelet agents and statins should be reviewed. If LVEF is 35–45% but the patient is otherwise at 
lower risk, heart failure medications including beta-blockers should be considered. In preclinical 
studies, metoprolol and carvedilol have been beneficial, and these beta-blockers could be used unless 
contraindicated (e.g., reversible airways disease).
120, 121
 Some experts suggest that vasoactive drugs, 
including angiotensin-converting enzyme (ACE) inhibitors, should be avoided in patients with normal 
cardiac output, as some Takotsubo syndrome patients may have altered peripheral sympathetic nerve 
activity associated with low peripheral vascular resistance. 
Takotsubo syndrome patients in the lower-risk category should be followed for 3–6 months after 
discharge. The follow-up should include review of medications and cardiac imaging to confirm 
recovery of the RWMA. 
Management of higher-risk cases of Takotsubo syndrome 
General considerations 
Takotsubo syndrome cases meeting criteria for higher risk should be monitored in a level 2 
environment (e.g. coronary care unit or high-dependency unit) with continuous ECG monitoring and 
access to resuscitation equipment for at least 72 hours after presentation, when risk of life-threatening 
complications is greatest.
92
 The opinion of a specialist (e.g. cardiologist with a special interest in heart 
failure) should be sought where available. Patients with decreased cardiac output should be 
considered for regular echocardiographic monitoring. Cessation of drugs with sympathomimetic 
properties is advised (e.g., catecholamines, β2-agonists). Beta-blockers may be considered in 
haemodynamically stable patients and in patients with atrial or ventricular tachyarrhythmias. In 
patients with haemodynamically significant LVOTO (LVOTO >40 mm Hg and systolic blood 
pressure <110 mm Hg), treatment with a beta-blocker or selective alpha-1 agonist (e.g. 
phenylephrine) should be considered. Short-acting intravenous beta-blockers are preferred acutely, 
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providing no contraindications exist. If any clinical features suggest phaeochromocytoma, appropriate 
diagnostic studies should be performed before beta-blocker treatment is started. 
In patients with Takotsubo syndrome complicated by cardiogenic shock, continuous 
haemodynamic monitoring may help guide treatment selection. In more severe cases of cardiogenic 
shock with progressive end-organ dysfunction, avoidance or withdrawal of exogenous catecholamines 
is recommended, as they probably exacerbate or prolong the acute phase. Treatment options include 
mechanical support for acute cardiogenic shock, such as temporary LV assist devices (LVAD) and 
extracorporeal membrane oxygenation (ECMO) (see below), or if those options are not available, 
low-dose levosimendan infusion as a catecholamine-sparing positive inotrope. No evidence currently 
exists to guide treatment choice in these complex patients, and new trial evidence is required. Expert 
consensus suggests that unstable patients with low cardiac output and cardiogenic shock be managed 
in a high-dependency unit (level 2) or intensive care unit (level 3) and that early for LVAD or ECMO 
support be considered. The use of inotropes (e.g., dobutamine, norepinephrine, epinephrine, 
dopamine, milrinone, and isoproterenol) should be generally regarded as contraindicated in Takotsubo 
syndrome,
122
 as further activation of catecholamine receptors or their downstream molecular pathways 
might worsen the clinical status and prognosis of patients with Takotsubo syndrome and cardiogenic 
shock.
120, 123, 124
 
Mechanical support 
Intra-aortic balloon counterpulsation (IABP) has been used to treat cardiogenic shock due to 
Takotsubo syndrome. However, in light of recent neutral data from the IABP-SHOCK II trial and the 
fact that IABP may worsen dynamic LVOTO, the consensus viewpoint is to avoid use of IABP in 
Takotsubo syndrome patients. If a patient with primary Takotsubo syndrome is deteriorating and has a 
low cardiac output, cardiogenic shock, and progressive multiorgan failure, specialist advice about 
ECMO or LVAD as a bridge-to-recovery is recommended, as there is an excellent chance that 
ventricular function will recover fully.
125-128
 In cases of secondary Takotsubo syndrome complicated 
by cardiogenic shock, the nature, severity, and prognosis of the underlying medical condition will 
determine whether mechanical cardiac support is warranted during the acute phase. 
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Levosimendan 
The role of levosimendan is more controversial, with mixed expert opinion based on preclinical and 
limited clinical experience.
120, 129-133
 In the absence of access to emergency mechanical support, 
levosimendan may be preferable to other inotropes such as dobutamine and epinephrine in patients 
who have advancing cardiogenic shock and multiorgan failure. Prospective randomised studies are 
required to assess the safety and efficacy of levosimendan in patients with Takotsubo syndrome and 
acute heart failure. 
Access to all these advanced care options may vary and depend upon local expertise. 
Preventing thromboembolism 
Takotsubo syndrome may be associated with blood hypercoagulability reflecting the vasoconstrictor, 
platelet activation, or prothrombotic effects of high catecholamine levels.
134
 Thromboembolism is a 
complication in ~4% of Takotsubo syndrome patients. Many patients with Takotsubo syndrome will 
initially receive antithrombotic treatment for suspected STEMI including dual antiplatelet therapy 
(aspirin and P2Y12 receptor antagonists) and unfractionated or low-molecular-weight heparin. Once 
MI is excluded, consensus supports withdrawal of P2Y12 receptor antagonists (clopidogrel, prasugrel, 
ticagrelor). 
Oral anticoagulation is recommended if intraventricular thrombus is detected in a patient with 
Takotsubo syndrome in the absence of high bleeding risk. Apical thrombus resolution and LV 
function recovery should be documented before anticoagulation is withdrawn. The role of 
prophylactic anticoagulation remains to be determined. Therapeutic low-molecular-weight heparin 
should be considered in cases with extensive segmental akinesia or atrial fibrillation. 
Follow-up after hospital discharge 
Regardless of the severity of their acute episode, all patients should be offered a follow-up assessment 
at 3–6 months. It should include repeat cardiac imaging to confirm the resolution of the acute RWMA 
and ECG changes observed and to exclude MI by CMR with LGE if not performed during the acute 
admission and in borderline cases. A review of medication will ensure that any drug therapy for ACS 
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has been stopped. If LV function has recovered, weaning from the ACE inhibitor and beta-blocker can 
be considered in the absence of other indications. 
There is currently no evidence to guide the long-term management of patients after an episode of 
Takotsubo syndrome. Some patients have persistent cardiac symptoms after LVEF and RWMA have 
normalised,
135
 including chest pain, palpitations, and exertional breathlessness. Further investigations 
to define the cause and treatment are advised, as ongoing cardiac abnormalities (e.g., microvascular 
perfusion abnormalities, atrial arrhythmias) may arise months or years after the acute episode. 
Given the high risk of complications during the acute phase, patients with recurrent episodes of 
Takotsubo syndrome may warrant long-term follow-up to identify strategies to minimise or prevent 
further recurrence (see below). 
Preventing recurrence 
Prevention of recurrent Takotsubo syndrome has not been demonstrated in any study. Intuitively, 
beta-blockers may provide some protection against future catecholamine surges. However, 
recurrences have been reported in patients taking beta-blockers, and one meta-analysis found no 
impact of beta-blockers on the risk of recurrence, although recurrence was infrequent in both arms.
136, 
137
 Nevertheless, there may be a role for beta-blockers in selected patients, such as those with 
evidence of persistently elevated sympathetic tone, ongoing cardiac symptoms (not clinically 
recovered), and persistent anxiety and those with recurrent Takotsubo syndrome. 
There is evidence that anxiety states are more frequent in some patients with Takotsubo 
syndrome. Given the high frequency of stressful triggers in cases of primary Takotsubo syndrome, the 
psychological response to stress is another potential therapeutic target. The benefit of psychological 
counselling and cognitive behavioural therapy remains to be determined, but they may have a role in 
selected cases of recurrence triggered by emotional stressors and in cases of confirmed anxiety 
disorder. 
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Late-presenting cases (Box 5) 
Some patients have delayed access to medical care or request a retrospective assessment of ‘troponin-
positive chest pain episodes with normal coronary arteries’ lacking a diagnosis. A careful review of 
the history and risk factor profile may alter the probability that the episode in question was an acute 
Takotsubo syndrome (Box 5). Review of ECGs and cardiac biomarkers, if available, may aid 
detection of the classical features that discriminate Takotsubo syndrome from ACS. Cardiac imaging, 
including echocardiography and CMR with LGE, helps exclude MI and other possible conditions. The 
role of cardiac mIBG is exploratory and may help demonstrate regional abnormalities of cardiac 
sympathetic innervation in a classical anatomical pattern and in the absence of infarction or 
alternative explanation. 
Conclusion and future directions 
Takotsubo syndrome is a fascinating acute heart failure syndrome, now increasingly recognised by the 
medical community. Many facets of this condition are incompletely understood or characterised, and 
current knowledge to guide optimal clinical management is limited. However, the increasing 
incidence and the high frequency of complications during the acute phase underpin the need to 
improve care pathways for patients with Takotsubo syndrome. 
To date, clinical reports are mostly based on relatively small cohorts and case series. Therefore, 
the recommendations of this Position Statement reflect the consensus of expert opinion (level of 
evidence C). Randomised controlled trials are needed to identify optimal diagnostic and management 
strategies for Takotsubo syndrome. The potential for national and international registries to collect 
larger numbers of patients prospectively should aid understanding of the epidemiology and natural 
history. Takotsubo syndrome networks may also provide the infrastructure for research studies and, in 
particular, given the lack of current evidence-based treatments, for assessing novel therapeutic 
strategies. Individual hospitals may see no more than ~5–30 cases per annum, and broader networks 
are required to collect larger numbers of patients. Several countries have started to coordinate data 
collection in regional or national registries, and one international registry, the InterTAK registry 
Lyon et al. / 28 
(NCT01947621), has been launched to gather 10-year follow-up data on a large cohort of 
prospectively enrolled patients with confirmed Takotsubo syndrome. 
This is the first Position Statement from the ESC Heart Failure Association for this acute heart 
failure syndrome. It will be updated when further advances in the understanding and management of 
Takotsubo syndrome are available and particularly when results from randomised controlled trials are 
available to provide a stronger evidence base for clinical decision-making. 
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Abbreviations 
ACE  angiotensin-converting enzyme 
ACS  acute coronary syndrome 
BNP  brain natriuretic peptide 
CCTA  coronary computed tomography angiography 
CMR  cardiac magnetic resonance 
ECG  electrocardiogram 
ECMO  extracorporeal membrane oxygenation 
ESC  European Society of Cardiology 
HCM  hypertrophic cardiomyopathy 
HFA Heart Failure Association of the European Society of Cardiology 
IABP intra-aortic balloon counterpulsation 
LGE  late gadolinium enhancement 
LV  left ventricular 
LVAD  left ventricular assist device 
LVOTO left ventricular outflow tract obstruction 
mIBG  iodine-123 metaiodo-benzyl-guanidine 
MI  myocardial infarction 
MLV  mid left ventricular variant 
NSTEMI non-ST-elevation myocardial infarction 
NT-proBNP N-terminal fragment of brain natriuretic peptide 
RWMA regional wall motion abnormality 
RV  right ventricular 
STEMI  ST-elevation myocardial infarction 
VT  ventricular tachycardia 
VF  ventricular fibrillation 
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Figure legends 
Figure 1. Anatomical variants of Takotsubo syndrome. (A) Ventriculographic appearances showing 
paired end-diastolic image (above) and end-systolic image (below) of a mid-ventricular variant (A and 
B), an inverted Takotsubo variant (C and D), and a typical apical Takotsubo variant (E and F). 
Adapted from Haghi et al.
138
 (B) CMR appearances showing paired acute end-diastolic (left), acute 
end-systolic (centre), and follow-up end-systolic (right) images for typical apical Takotsubo syndrome 
(top row), mid-ventricular variant (middle row), and inverted Takotsubo variant (lower row) 
(reproduced from Eitel et al
35
). (C) Biventricular involvement with LV and RV apical hypokinesia. 
White arrows highlight regions of hypokinesia in the end-systolic four-chamber view (adapted from 
Haghi et al
36
).  
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Box 1 HFA diagnostic criteria for Takotsubo syndrome 
1. Transient regional wall motion abnormalities of LV or RV myocardium which are frequently, 
but not always, preceded by a stressful trigger (emotional or physical).  
2. The regional wall motion abnormalities usually* extend beyond a single epicardial vascular 
distribution, and often result in circumferential dysfunction of the ventricular segments 
involved. 
3. The absence of culprit atherosclerotic coronary artery disease including acute plaque rupture, 
thrombus formation and coronary dissection or other pathological conditions to explain the 
pattern of temporary left ventricular dysfunction observed (e.g. hypertrophic cardiomyopathy, 
viral myocarditis). 
4. New and reversible electrocardiography (ECG) abnormalities (ST-segment elevation, ST 
depression, LBBB
†
, T-wave inversion, and/or QTc prolongation) during the acute phase (3 
months). 
5. Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during the acute phase. 
6. Positive but relatively small elevation in cardiac troponin measured with a conventional assay 
(i.e., disparity between the troponin level and the amount of dysfunctional myocardium 
present).
‡ 
7. Recovery of ventricular systolic function on cardiac imaging at follow-up (3–6 months).§ 
*Acute, reversible dysfunction of a single coronary territory has been reported. 
†
Left bundle branch block may be permanent after Takotsubo syndrome, but should also alert 
clinicians to exclude other cardiomyopathies. T-wave changes and QTc prolongation may take many 
weeks to months to normalize after recovery of LV function. 
‡
Troponin-negative cases have been reported, but are atypical. 
§
Small apical infarcts have been reported. Bystander subendocardial infarcts have been reported, 
involving a small proportion of the acutely dysfunctional myocardium. These infarcts are insufficient 
to explain the acute RWMA observed. 
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Box 2 Differences between Takotsubo syndrome and acute myocarditis 
Category Takotsubo syndrome Acute Myocarditis 
Gender and age  90% female. 
Majority >50 years and 
postmenopausal. 
No sex prevalence. 
More frequent in the young. 
Preceding events Stressor trigger identifiable in ~70% 
cases. 
Symptoms and signs of infection often 
present (fever, chills, headache, muscle 
aches, general malaise, cough, nausea, 
vomiting, diarrhoea).  
Cardiac symptoms Chest pain, dyspnoea, palpitations. Chest pain, dyspnoea, peripheral 
oedema, fatigue and palpitations. 
Clinical signs Pericardial rub rare. Pericardial rub may be present. 
ECG at admission ST changes like STEMI or NSTEM. 
Deep T wave inversion. 
QT prolongation. 
Rarely normal. 
ST-segment elevation or depression, 
negative T-wave, bundle branch block, 
atrioventricular block, low voltage, 
and/or ventricular arrhythmias. 
Normal in several cases. 
Cardiac enzymes Low/moderate troponin rise. 
Discrepancy between the large amount 
of dysfunctional myocardium and peak 
troponin level. 
Frequently significant troponin rise, 
proportional to the hypokinetic area. 
Normal in several cases. 
Other biomarkers CRP mildly elevated unless infective 
trigger. 
BNP moderately or significantly 
elevated. 
Erythrocyte sedimentation rate and 
CRP elevated. BNP basically elevated. 
Acute viral serology may be detected. 
Echocardiography Apical ballooning, anatomical variants, 
“circumferential pattern”, LVOTO, 
RV involvement, transient MR. 
Localized or diffuse wall motion 
abnormalities of LV and/or RV 
ventricular dilatation, increased wall 
thickness, pericardial effusion. 
CMR Imaging High T2 signal intensity (oedema), 
LGE usually absent acutely. If present 
acutely patchy LGE which usually 
resolves at follow-up. Absence of 
typical infarct LGE pattern. 
High T2 signal intensity (oedema), late 
gadolinium enhancement with non-
ischaemic distribution (often 
epicardial). Absence of typical infarct 
LGE pattern. 
Histological findings Contraction band necrosis. Infiltration of many inflammatory 
cells. Interstitial oedema. 
Viral genome, separation of 
virus or identification of 
virus by antibody titre 
Rare and usually absent where 
measured. 
Often positive. 
Prognosis 50% of cases have acute 
complications, 4–5% mortality. 
Variable but majority full recovery. 
Highest mortality with fulminant 
myocarditis. 
Therapy Supportive. Supportive. Immunosuppression in 
severe cases if giant-cell myocarditis 
suspected. 
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Box 3 Summary of pathophysiological hypotheses 
Vascular Acute multivessel coronary spasm. 
 Aborted myocardial infarction with spontaneous recanalization. 
Acute increased ventricular afterload. 
Myocardial Acute LVOTO. 
Direct catecholamine-mediated myocardial stunning. 
Vascular and myocardial Integrated cardiovascular physiology (a cardio-circulatory 
syndrome). 
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Box 4 HFA Risk stratification in Takotsubo syndrome  
Risk Factor Higher Risk Lower Risk 
Major Risk Factors   
Age ≥75 years See Minor Risk Factors 
Systolic BP <110 mm Hg ≥110 mm Hg 
Clinical pulmonary oedema
†
 Present Absent 
Unexplained syncope, VT or VF Present Absent 
LVEF <35% See Minor Risk Factors 
LVOTO ≥40 mm Hg Absent or <40 mm Hg 
Mitral regurgitation
‡
 Present Absent 
Apical thrombus Present Absent 
New VSD or contained Present Absent 
LV wall rupture   
Minor risk factors   
Age 70–75 years 
<70 years 
ECG   
QTc ≥500 ms <500 ms 
Pathological Q waves Present Absent 
Persistent ST elevation
§
 Present Absent 
LVEF 35–45% ≥45% 
Physical stressor Present Absent 
Natriuretic peptides   
BNP ≥ 600 pg/ml <600 pg/ml 
NT-proBNP ≥ 2000 pg/ml NT-proBNP <2000 pg/m 
Bystander obstructive CAD Present Absent 
Biventricular involvement Present Absent 
VSD, ventricular septal defect; CAD, coronary artery disease. 
*See minor criteria regarding LVEF in absence of major criteria. 
†
Lower zone (basal) pulmonary rales on clinical examination or evidence on chest x-ray. 
‡
Moderate or severe mitral regurgitation. 
§
≥3 days. 
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Box 5 HFA management strategy for late-presenting Takotsubo syndrome cases and 
retrospective review 
Late or retrospective review 
Review history 
Review risk factors 
Review ECGs 
Review cardiac biomarker profile (serum natriuretic peptides and troponin) from acute episode 
Consider: 
Cardiac MRI + LGE (exclude MI, HCM) 
CCTA (exclude obstructive CAD) 
Cardiac mIBG 
HCM, hypertrophic cardiomyopathy; CAD, coronary artery disease. 
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Table 1 Triggers for secondary Takotsubo syndrome 
Endocrine 
e.g., Phaeochromocytoma, thyrotoxicosis (endogenous and iatrogenic), SIADH, Addisonian crisis, 
multiple endocrine neoplasia 2A syndrome, hyperglycaemic hyperosmolar state, hyponatremia, severe 
hypothyroidism, Addison’s disease, adrenocorticotropin hormone deficiency, autoimmune 
polyendocrine syndrome II 
Neurological and neurosurgical 
Acute neurosurgical emergencies (e.g., subarachnoid haemorrhage, acute head injury, acute spinal 
injury) 
Acute neuromuscular crises, especially if involving acute ventilatory failure (e.g. acute myasthenia 
gravis, acute Guillain-Barré syndrome) 
Epileptic seizures, limbic encephalitis, ischemic stroke, posterior reversible encephalopathy syndrome 
Respiratory 
Acute exacerbation of asthma or chronic obstructive airways disease 
(especially with excessive use of inhaled β2agonists) 
Acute pulmonary embolism 
Acute pneumothorax 
Obstetric 
e.g. miscarriage, labour, emergency Caesarean section 
Psychiatric 
Acute anxiety attack/panic disorder 
Attempted suicide 
Drug-withdrawal syndromes 
Electroconvulsive therapy 
Gastrointestinal 
e.g. acute cholecystitis, biliary colic, acute pancreatitis, severe vomiting, severe diarrhoea, 
pseudomembranous colitis, peritonitis 
Infection 
Severe sepsis 
Babesiosis 
Cardiological 
Dobutamine stress echocardiography 
Radiofrequency arrhythmia ablation 
Pacemaker implantation 
Electrical DC cardioversion for atrial fibrillation 
Post cardiac arrest including ventricular fibrillation 
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Haematological 
Blood transfusions 
Thrombotic thrombocytopaenic purpura 
Surgical 
Many cases have been reported during induction of general anaesthesia or during non-cardiac surgery 
or interventional procedures under local or general anaesthesia (e.g., cholecystectomy, hysterectomy, 
rhinoplasty, caesarean section, radiofrequency liver ablation, radiotherapy, colonoscopy, difficult 
urinary catheterization, carotid endarterectomy) 
Medication and illicit drugs 
Epinephrine injection 
Nortriptyline overdose, venlafaxine overdose, albuterol, flecanide, metoprolol withdrawal, 5-
fluorouracil, duloxetine 
Cocaine abuse 
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Table 2 Anatomical variants of Takotsubo syndrome 
Variant Estimated Prevalence 
Apical with or without MLV variant (typical)  75–80% 
Mid LV  ~10–15% 
Inverted or basal  ~5% 
Biventricular  Clinical <0.5%; CMR 33% 
Right ventricular 
Apical tip sparing 
Unknown 
Unknown 
Possible atypical variants  
Global  Unknown 
Focal  Unknown 
Lyon et al. / 50 
Table 3 In-hospital and long-term outcome of Takotsubo syndrome 
Complication/outcome Frequency 
Acute complications  
RV involvement 18–34% 
Acute heart failure 12–45% 
LV outflow tract obstruction 10–25% 
Mitral regurgitation 14–25% 
Cardiogenic shock 6–20% 
Arrhythmias  
Atrial fibrillation 5–15% 
Ventricular arrhythmias 4–9% 
Bradycardia, asystole 2–5% 
Thrombus formation 2–8% 
Pericardial tamponade <1% 
Ventricular wall rupture  <1% 
In-hospital mortality 1–4.5% 
Recurrence 5–22% 
5-year mortality 3–17% 
 
